Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323784 | 1.00 | ACE (0.52) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL13323781 | 0.91 | KLK5 (0.48) | CYP3A4SCN9ACTSSCTSLCTSB | |
| SCHEMBL2367071 | 0.91 | KLK5 (0.48) | CYP3A4SCN9ACTSSCTSLCTSB | |
| SCHEMBL27683505 | 0.91 | KLK5 (0.48) | CYP3A4SCN9ACTSSCTSLCTSB | |
| SCHEMBL479035 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL30655780 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL29401567 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL479037 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL606221 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL | |
| SCHEMBL30547269 | 0.90 | ACE (0.61) | ACECYP3A4SCN9ACTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7531507-B2 | Acylated nonadepsipeptides containing pyridyl alanine residues | AICURIS GMBH & CO. KG (DE) | 2009-05-12 | — | — | US | disclosed |
| US-7531507-B2 | Acylated nonadepsipeptides containing pyridyl alanine residues | AICURIS GMBH & CO. KG (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | ACE 1494/4885CYP3A4 4034/4885SCN9A 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.